We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Systematic Evaluation of Human Explant Model Systems Engineering (SEEDLING)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04671654
Recruitment Status : Recruiting
First Posted : December 17, 2020
Last Update Posted : December 21, 2021
German Cancer Research Center
Information provided by (Responsible Party):
Niels Halama, University Hospital Heidelberg

Brief Summary:
All current forms of therapy for tumor patients are essentially based on clinical, genomic or histopathological criteria for the choice of therapy. However, the change in the tissue during therapy is of particular importance for patients, both with regard to the development of resistance and the side effect profile. This applies in particular to immunotherapies and their use in advanced tumor diseases. Preliminary work on the fully human tumor explant model has shown that the use of human donor tissue in the context of a special bioreactor makes it possible to improve the possibilities of predicting and better understanding the mechanism of action of a therapeutic agent. Since there is a considerable need for personalized and thus improved therapy management in the field of oncology, the aim of this study is on the one hand to improve the decisive tissue parameters for the cultivation of human donated material and on the other hand to understand the basic reaction patterns of the tissue to therapies.

Condition or disease
Solid Tumor, Adult

Detailed Description:
Personalized therapy is still one of the great goals of oncology. In view of the success of checkpoint inhibitor therapies in selected solid tumors, the question remains why other tumor diseases do not respond in the same way to the therapy. However, this is not only limited to immunotherapies. In principle, the understanding of the dynamic changes in a patient's tissue has so far been very limited, both for predicting a therapy success and with regard to the mechanistic understanding of how a therapy works. Model systems for diseases are often animal models that reproduce the complexity of a multi-organ system, but show significant differences to humans at the tissue level and therefore have only little informative value. Cell culture experiments, on the other hand, have only little informative value with regard to the overall behavior of a tissue or even an organ or the disease situation. "Naturalistic" co-culture in the Petri dish (such as with organoid systems) does not allow any sensible transferable insights, even if complex cell compositions of fibroblasts, endothelium or immune cells are used. In contrast, there is another problem for in vivo tumor models: either there is a lack of flexibility with regard to the structural context or the species-specific system properties do not allow any conclusions to be drawn about the situation in humans. This is a massive limitation, especially for translational studies. The Tumor Explant Model System developed by us allows the structural integrity of the tissue context to be maintained in the context of obtaining a biopsy or removing a resection. The tissue sample obtained in this way is kept in equilibrium via a bioreactor and can thus be used for tests or is preserved in its context of the tissue. It is also possible in the sense of a personalized diagnosis and therapy to take into account the individual bandwidth of the composition of the tumor microenvironment. This approach has already been validated in a prospective study and the transferability of the results from the explant models to humans has been proven. In this situation, the systematic construction of explant models for other tumor entities and the use of these models for therapy development and for better understanding of pathoregulation in tissues. In addition to the tissue samples donated by the study participants, blood cells can also be used for testing the tissue.hand to understand the basic reaction patterns of the tissue to therapies.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Systematic Evaluation of Human Explant Model Systems Engineering
Actual Study Start Date : August 1, 2020
Estimated Primary Completion Date : August 2025
Estimated Study Completion Date : August 2025

Primary Outcome Measures :
  1. Tissue Biopsy Specimen vs Tumor Explant Model Prediction [ Time Frame: up to 24 weeks ]
    Comparison of serial biopsy measurements to Explant Model measurements in the context of individual Patient variability, Serial biopsy timepoints can vary between 1 day up to 24 weeks

Biospecimen Retention:   Samples With DNA
Tumor Explant Models

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients with solid tumor diseases in a non-curative setting.

Inclusion Criteria:

  • Tissue material for Explant Model generation available or accessible

Exclusion Criteria:

  • curatively resected/treated tumors

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04671654

Layout table for location contacts
Contact: Azaz Ahmed, Dr. med. +49-6221-56-7229 Azaz.Ahmed@med.uni-heidelberg.de
Contact: Niels Halama, Dr. med. +49-6221-56-4801 Niels.Halama@nct-heidelberg.de

Layout table for location information
University of Heidelberg / NCT Recruiting
Heidelberg, Germany, 69120
Contact: Niels Halama, PD Dr. med    +49 6221-56-7229    Niels.Halama@med.uni-heidelberg.de   
Contact: Azaz Ahmed, Dr. med.    +49-6221-56-7229    Azaz.Ahmed@med.uni-heidelberg.de   
Sub-Investigator: Anja Williams, Dr.         
Sub-Investigator: Axel Benner         
Sponsors and Collaborators
University Hospital Heidelberg
German Cancer Research Center
Layout table for investigator information
Study Chair: Dirk Jaeger, Prof. Dr. med. University Hospital Heidelberg
Layout table for additonal information
Responsible Party: Niels Halama, Head of Department Translational Immunotherapy DKFZ, University Hospital Heidelberg
ClinicalTrials.gov Identifier: NCT04671654    
Other Study ID Numbers: U1111-1254-2831-S-507/2019
U1111-1254-2831 ( Other Identifier: World Health Organization (WHO) )
First Posted: December 17, 2020    Key Record Dates
Last Update Posted: December 21, 2021
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Niels Halama, University Hospital Heidelberg:
targeted therapy